Adjuvant chemotherapy after curative resection for gastric cancer in non-asian patients: Revisiting a meta-analysis of randomised trials

European Journal of Cancer

Volumn 35, Issue 7, 1999, Pages 1059-1064

  Earle, C C ^a   Maroun, J A ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Adjuvant chemotherapy; Meta analysis; Stomach cancer

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; SEMUSTINE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; STOMACH CARCINOMA;

CHEMOTHERAPY, ADJUVANT; HUMANS; RANDOMIZED CONTROLLED TRIALS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 0033166516     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00076-3     Document Type: Article

References (51)

1. Physician Data Query. Gastric Cancer. CancerNet, 1996, April.
2. Agboola O. Adjuvant treatment in gastric cancer. Cancer Treatment Reviews. 20:1994;217-240.
3. Middleton G., Cunningham D. Current options in the management of gastrointestinal cancer. Ann. Oncol. 6(Suppl. 1):1995;S17-S26.
4. American Joint committee on Cancer. Manual for Staging of Cancer. Philadelphia, JB Lippincott Company, 1992, 63.
5. DeVita V.T. Jr., Hellman S., Rosenberg S.A. Cancer. Principles and Practice of Oncology:1993;J.B. Lippincott Co, Philadelphia. 277.
6. Hermans J., Bonenkamp J.J., Boon M.C.et al. Adjuvant therapy after curative resection for gastric cancer. meta-analysis of randomized trials J. Clin. Oncol. 11:1993;1441-1447.
7. Pignon J.P., Ducreux M., Rougier P. Meta-analysis of adjuvant chemotherapy in gastric cancer. a critical reappraisal J. Clin. Oncol. 12:1994;877-878.
8. Nakajima T., Takahashi T., Takagi K. Comparison of fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J. Clin. Oncol. 2:1984;1366-1371.
9. Hermans J., Bonenkamp H. In reply (letter). J. Clin. Oncol. 12:1994;879-880.
10. Krook J.E., O'Connell M.H., Wieand H.S.et al. A prospective, randomised evaluation of intensive course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer. 67:1991;2454-2458.
11. Tsavaris N., Tentas K., Kosmidis P.et al. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy. 42:1996;220-226.
12. MacDonald J.S., Fleming T.R., Peterson R.F.et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma. a Southwest Oncology Group study Annals. Surg. Oncol. 2:1995;488-494.
13. Cirera L, Balil A, Batiste E, et al. Efficacy of adjuvant mitomycin C plus tegafur in stage III gastric cancer. Proc Am Soc Clin Oncol 1997, 16 (Abstr. 986).
14. Hagiwara A., Takahashi T., Kojima O.et al. Prophylaxis with carbon absorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet. 339:1992;629-631.
15. Lise M., Nitti D., Marchet A.et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regiment in resectable gastric cancer. J. Clin. Oncol. 13:1995;2757-2763.
16. Sautner T., Hofbauer F., Depisch D., Schiessel R., Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J. Clin. Oncol. 12:1994;970-974.
17. Chou F.F., Sheen-Chen S.M., Liu P.P., Chen F.C. Adjuvant chemotherapy for resectable gastric cancer. a preliminary report J. Surg. Oncol. 57:1994;239-242.
18. Neri B., de Leonardis B., Romano S.et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients. a multicentre randomised study Br. J. Cancer. 73:1996;549-552.
19. Carrato A., Diaz-Rubio E., Medrano J.et al. Phase III trial of surgery versus adjuvant chemotherapy with mitomycin and tegafur plus uracil (UFT), starting within the first week after surgery, for gastric adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 14:1995;468.
20. Haynes R.B., Wilczynske N., McKibbon K.A., Walker C.J., Sinclair J.C. Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J. Am. Med. Informatics Assoc. 1:1994;447-458.
21. Cuschieri A., Fayers P., Fielding J.et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer. preliminary results of the MRC randomised controlled surgical trial Lancet. 347:1996;995-999.
22. Dedrick R.L., Flessner M.F. Pharmacokinetic problems in peritoneal drug administration. tissue penetration and surface exposure J. Natl. Cancer Inst. 89:1997;480-487.
23. Moher D., Jadad A.R., Nichol G., Penman M., Tugwell P., Walsh S. Assessing the quality of randomized controlled trials. an annotated bibliography of scales and checklists Controlled Clin. Trials. 16:1995;62-73.
24. Berlin J.A., Laird N.M., Sacks H.S., Chalmers T. A comparison of statistical methods for combining event rates from clinical trials. Stat. in Med. 8:1989;141-151.
25. Sackett D.L., Deeks J.J., Altman D.G. Down with odds ratios! Evidence-based Medicine. 1:1996;164-166.
26. Felson D.T. Bias in meta-analytic research. J. Clin. Epidemiol. 45:1992;885-892.
27. Orwin R.G. A fail-safe N for effect size in meta-analysis. J. Educational Stats. 8:1983;157-159.
28. Petitti DB. In MKelsey JL, Marmot MG, Stolley PD, Vessey, MP, eds. Monographs in Epidemiology and Biostatistics. New York, Oxford University Press, 1994, 110.
29. Allum W.H., Hallissey M.T., Kelly K.A. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet. 1:1989;571-574.
30. Hallissey M.T., Dunn H.A., Ward L.C., Allum W.H. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer. five-year follow-up Lancet. 343:1994;1309-1312.
31. Jakesz R., Dittrich C., Funovics J.et al. The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology. 5-year results of a prospective randomized trial Recent Results Cancer Res. 110:1988;44-51.
32. Ochiai T., Sato H., Hayashi R.et al. Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial. Cancer Immunol. Immunother. 14:1983;167-171.
33. Yamamura Y., Nishimura M., Sakamoto J.et al. A randomized controlled trial of surgical adjuvant therapy with mitomycin C, 5-fluorouracil and OK-432 in patients with gastric cancer. Gan to Kagaku Ryoho. 13:1986;2134-2140.
34. Kim J.P. Immunochemosurgery as a new approach to reasonable treatment of advanced cancer. Ann. Acad. Med. Singapore. 17:1988;48-54.
35. Schiessel R., Funovics J., Schick B.et al. Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma. Results of a randomized trial. Acta Med. Aust. 16:1989;68-69.
36. Coombes R.C., Schein P.S., Chilvers C.E.D.et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer. J. Clin. Oncol. 8:1990;1362-1369.
37. Bonfanti G., Gennari L., Bozzette F.et al. Adjuvant treatments following curative resection for gastric cancer. The Italian Gastrointestinal Tumor Study Group. Br. J. Surg. 75:1988;1100-1104.
38. Engstrom P.F., Lavin P.T., Douglas H.O., Brunner K.W. Postoperative adjuvant 5-fluorouracil plus methyl CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group Study (EST 3275). Cancer. 55:1985;1868-1873.
39. Higgins G.A., Amadeo J.H., Smith D.E., Humphrey E.W., Keehn R.J. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology Group Report. Cancer. 52:1983;1105-1112.
40. Douglass H.O., Stablein D.M., Bruckner H.M.et al. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer. 49:1982;1116-1122.
41. Oxman A.D., Clarke M.J., Stewart L.A. From science to practice. meta-analyses using individual patient data are needed JAMA. 274:1995;845-846.
42. Huguier M., Destroyes H., Baschet C., Le Henand F., Bernard P.F. Gastric carcinoma treated by chemotherapy after resection: a controlled study. J. Surg. 139:1980;197-199.
43. Schlag P., Schreml W., Gaus W.et al. Adjuvant 5 fluorouracil and BCNU chemotherapy in gastric cancer. 3-year results. Recent Results Cancer Res. 80:1982;277-283.
44. Grau J.J., Estape J., Alcobendas F. Positive results of adjuvant mitomycin C in resected gastric cancer. a randomised trial on 134 patients Eur. J. Cancer. 29A:1993;340-342.
45. Serlin O., Wolkoff H.S., Amadeo H.M., Keehn R.J. Use of 5 fluorodeoxuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer. 24:1969;223-228.
46. Dent D.M., Werner I.D., Noris B.et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer. 44:1979;385-391.
47. Blake J.R.S., Hardcastle J.D., Wilson R.G. Gastric cancer. a controlled trial of adjuvant chemotherapy following gastrectomy Clin. Oncol. 7:1981;13-27.
48. Alcobendas F., Milla A., Estape H., Curto C., Pera C. Mitomycin C as an adjuvant in resected gastric cancer. Ann. Surg. 198:1983;13-17.
49. Fielding J.W.L., Fagg S.L., Jones B.G.et al. An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer. British Stomach Cancer Group World J. Surg. 7:1983;390-399.
50. Allum W.H., Hallissey M.T., Ward L.C.et al. A controlled prospective randomized trail of adjuvant chemotherapy or radiotherapy in resectabel gastric cancer. Interim report. British Stomach Cancer Group. Br. J. Cancer. 60:1989;739-744.
51. Estape J., Grau J.J., Lcobendas F.et al. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann. Surg. 213:1991;219-221.